Targeted therapies in head and neck cancer: Past, present and future

Reviews on Recent Clinical Trials

Volumn 3, Issue 3, 2008, Pages 156-166

  Rapidis, Alexander D ^a   Vermorken, Jan B ^b   Bourhis, Jean ^c  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Bevacizumab; Cetuximab; EGFR; Head and neck cancer; Panitumumab; Targeted therapies

Indexed keywords

ALPHA2B INTERFERON; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; HUMAX EGFR; IRINOTECAN; LAPATINIB; MATUZUMAB; METHOTREXATE; MONOCLONAL ANTIBODY; NIMOTUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEMETREXED; PLACEBO; PLATINUM; PLATINUM COMPLEX; SORAFENIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALUTUMUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; VASCULOTROPIN A;

ACNE; ADJUVANT THERAPY; ARTICLE; BLEEDING; BLEPHARITIS; BREAST CANCER; CANCER RECURRENCE; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVITIS; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EYE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; HYPOPHARYNX CARCINOMA; HYPOTENSION; INFECTION; INTENSITY MODULATED RADIATION THERAPY; LARYNX CARCINOMA; LIVER CELL CARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NEUTROPENIA; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PUNCTATE KERATITIS; RADIATION DERMATITIS; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREMOR; WOUND HEALING IMPAIRMENT; XEROSIS; ADJUVANT CHEMOTHERAPY; DRUG ANTAGONISM; HEAD AND NECK TUMOR; MULTIMODALITY CANCER THERAPY; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 54049137661     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488708785700285     Document Type: Article

References (109)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-92.
3. Pivot X, Villanueva C. Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007; 18(Suppl 2): ii65-ii6.
4. Bernier J, Schneider D. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck? Eur J Cancer 2007; 43: 35-45.
5. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-8.
6. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 2081-6.
7. Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004; 22: 4665-73.
8. Schantz SP, Harrison LB, Forastiere A. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: DeVita VT, Hellman SA, Rosenberg SA Eds.: Cancer. Principles and practice of oncology, Edition 6th. Philadelphia: Lippincott Williams & Wilkins 2001; 797-860.
9. Leon X, Hitt R, Constenla M, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol) 2005; 17: 418-24.
10. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002; 94: 1593-611.
11. Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824-8.
12. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-6.
13. Maurizi M, Almadori G, Ferrandina G, et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 1996; 74: 1253-7.
14. Specenier PM, Vermorken JB. Targeted therapies in head and neck cancer. Targeted Oncol 2007; 2: 73-88.
15. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006; 12: 5268-72.
16. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007; 98: 1275-80.
17. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 2004; 173: 4699-707.
18. Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25: 3712-8.
19. Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005; 65: 3328-35.
20. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of antiepidermal growth factor receptor monoclonal antibodies plus cisdiamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53: 4637-42.
21. Higgins B, Kolinsky K, Smith M, et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 2004; 15: 503-12.
22. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000; 6: 2166-74.
23. Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002; 29: 47-50.
24. Shintani S, Li C, Mihara M, et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer 2003; 107: 1030-7.
25. Stewart CF, Leggas M, Schuetz JD, et al. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 2004; 64: 7491-9.
26. Blagosklonny MV. How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer Biol Ther 2005; 4: 1307-10.
27. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004; 64: 5355-62.
28. Matar P, Rojo F, Cassia R, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 2004; 10: 6487-501.
29. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
30. Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007; 25: 2191-7.
31. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006; 24: 1072-8.
32. Suntharalingam M, Taylor R, Wolf J, et al. Initial report of phase II trial of weekly cetuximab, CBDCA, paclitaxel and daily RT in patients with locally advanced SCCHN. Proceedings of the Multidisciplinary Head and Neck Cancer Symposium, January 18-20, California, USA 2007; Abstract presentation 5.
33. Merlano M, Numico G, Russi EG, et al. Cetuximab (C-mab) and chemo-radiation (CT-RT) for loco-regional advanced squamous cell carcinoma of the head and neck (HNC): A phase II study. J Clin Oncol 2007; 25(18S): Abstract 6043.
34. Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22: 1646-54.
35. Wirth LJ, Posner MR, Tishler RB, et al. Phase I study of panitumumab, chemotherapy and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): Early results. J Clin Oncol 2007; 25(18S): Abstract 6083.
36. Herchenhorn D, Dias FL, Pineda RM, et al. Phase II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2007; 25(18S): Abstract 6033.
37. Savvides P, Greskovich J, Bokar J, et al. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). J Clin Oncol 2007; 25(18S): Abstract 6068.
38. Arias de la Vega F, Herruzo I, de las Heras M, et al. Phase I/II study of concurrent erlotinib and chemoradiation for post-resected locally advanced squamous head and neck cancer (HNSCC): A GICOR study. J Clin Oncol 2007; 25(18S): Abstract 16544.
39. Savvides P, Agarwala SS, Greskovich J, et al. Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). J Clin Oncol 2006; 25(18S): Abstract 5545.
40. Rueda A, Medina JA, Mesia R, et al. Gefitinib plus concomitant boost accelerated radiation (AFX-CB) and concurrent weekly cisplatin for locally advanced unresectable squamous cell head and neck carcinomas (SCCHN): A phase II study. J Clin Oncol 2007; 25(18S): Abstract 6031.
41. Morris JC, Allen CT, Citrin D, et al. Pilot phase I study of gefitinib (GEF) in combination with paclitaxel (PAC) and radiation therapy (RT) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) and effects on epidermal growth factor receptor (EGFR) signaling pathway. J Clin Oncol 2007; 25(18S): Abstract 16526.
42. Harrington KJ, Bourhis J, Nutting CM, et al. A phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2006; 24(185): Abstract 5553.
43. Argiris A, Karamouzis MV, Heron DE, et al. Phase II trial of docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (RT), P, and E in locally advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2007; 25(18S): Abstract 6051.
44. Birnbaum AE, Johnson TT, Rathmore R, et al. Induction cetuximab (C) followed by C, paclitaxel (P), carboplatin (CP) and concurrent radiation (RI) for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2007; 25(18S): Abstract 16504.
45. Kuperman DI, Nussenbaum B, Thorstad W, Haughey B, Lewis J, Adkins D. Retrospective analysis of the addition of cetuximab to induction chemotherapy (IC) with docetaxel, cisplatin and 5-fluorouracil (TPF-C) for locally advanced squamous cell carcinoma of the head and neck (LA-HNSCC). J Clin Oncol 2007; 25(18S): Abstract 6072 and virtual presentation www.asco.org.
46. Wanebo HJ, Ghebremichael M, Burtness B, et al. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/ IV operable squamous cancer of the head and neck (ECOG, E2303). J Clin Oncol 2007; 25(18S): Abstract 6015.
47. Doss HH, Greco FA, Meluch AA, et al. Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/ gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: A phase I/II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2006; 24(18S): Abstract 5543.
48. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-54.
49. Hitt R, Irigoyen A, Nuñez J, et al. Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/ recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC). J Clin Oncol 2007; 25 (18S): Abstract 6012 and virtual presentation www.asco.org.
50. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-7.
51. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2005; 23: 5568-77.
52. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5578-87.
53. Buentzel J, de Vries A, Micke O. Experience with cetuximab plus paclitaxel/carboplatinum in primary platinum-resistant recurrent head and neck cancer. J Clin Oncol 2007; 25(18S): Abstract 6077.
54. Bier H, Hoffmann T, Hauser U, et al. Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol 2001; 47: 519-24.
55. Bastholt L, Specht L, Jensen K, et al. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol 2007; 85: 24-8.
56. Kim ES, Kies MS, Glisson BS, et al. Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2007; 25(18S): Abstract 5521.
57. Seiwert TY, Davis DW, Yan D, et al. pKDR/KDR ratio predicts response in a phase I/II pharmacodynamic study of erlotinib and bevacizumab for recurrent or metastatic head and neck cancer (HNC). J Clin Oncol 2007; 25(18S): Abstract 6021.
58. Vokes EE, Cohen EE, Mauer A, et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). Proc Am Soc Clin Oncol 2005; Abstract 5504.
59. Belon J, Irigoyen A, Rodriguez S, et al. Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 25(18S): Abstract 5563.
60. Abidoye OO, Cohen EE, Wang SJ, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2006; 24(18S): Abstract 5568.
61. Karamouzis MV, Friedland D, Johnson R, Rajasenan K, Branstetter B, Argiris A. Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): An interim analysis. J Clin Oncol 2007; 25(18S): Abstract 6049.
62. Seiwert TY, Haraf DJ, Cohen EE, et al. A phase I study of bevacizumab (B) with flourouracil (F) and hydroxyurea (H) with concomitant radiotherapy (X) (B-FHX) for poor prognosis head and neck cancer (HNC). J Clin Oncol 2007; 24(18S): Abstract 5530.
63. Williamson SK, Moon J, Huang CT, Guaglianone P, Wolf GT, Urba SG. A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial. J Clin Oncol 2007; 25(18S): Abstract 6044.
64. Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25: 3766-73.
65. Segaert S, Tabernero J, Chosidow O, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005; 3: 599-606.
66. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-33.
67. Iressa Prescribing Information (250 mg tablets). AstraZeneca. www.iressa-us.com 2005; Accessed September 2007.
68. Tarceva Prescribing Information. OSI Pharmaceuticals, Inc., and Genentech, Inc. www.gene.com/gene/products/information/oncology/tarceva/ insert.jsp 2007; Accessed September 2007.
69. Erbitux Prescribing Information. Merck KGaA. www.emea.europa.eu/ humandocs/Humans/EPAR/erbitux/erbitux.htm 2007; Accessed September 2007.
70. Vectibix Prescribing Information. Amgen Inc. www.amgenon cology.com/ prescribing_information/vectibix_pi.jsp 2007 (June); Accessed September 2007.
71. Dranko S, Kinney C, Ramanathan RK. Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer. Clin Colorectal Cancer 2006; 6: 224-5.
72. Melichar B, Nemcova I. Eye oomplications of cetuximab therapy. Eur J Cancer Care (Engl) 2007; 16: 439-43.
73. Budach W, Bolke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007; 357: 514-5.
74. Mydin AR, Armstrong JG. Acneiform rash secondary to œtuximab plus head and neck radiotherapy. Radiother Oncol 2007; 85(1): 171. Letter.
75. Bernier J, Bonner J, Vermorken JB, et al. Consensus guidelines for the management of radiation dermatitis and co-existing acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008; 19(1): 142-9.
76. Nexavar Prescribing Information. Bayer Pharmaceuticals Corporation. www.emea.europa.eu/humandocs/Humans/EPAR/nexavar/nexavar.htm 2007; Accessed November 2007.
77. Avastin Prescribing Information. Genentech Inc. www.gene.com/gene/ products/information/oncology/avastin/insert.jsp 2007; Accessed October 2007.
78. Amgen discontinues Vectibix treatment in PACCE trial evaluating Vectibix as part of triple combination regimen. www.amgen.com.media March 2007; Accessed September 2007.
79. Tol J, Koopman M, Rodenburg CJ, et al. Randomised phase III study of capecitabine, oxaliplatin and bevacizumab (CAPOXB) with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim safety analysis. Eur J Cancer 2007; 5(4): Abstract 3000.
80. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 6829-37.
81. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005; 23: 6838-45.
82. Erjala K, Sundvall M, Junttila TT, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006; 12: 4103-11.
83. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24: 4914-21.
84. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
85. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
86. Steiner P, Joynes C, Bassi R, et al. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin Cancer Res 2007; 13: 1540-51.
87. Mukohara T, Engelman JA, Hanna NH, et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005; 97: 1185-94.
88. Cohen EE, Lingen MW, Martin LE, et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 2005; 11: 8105-8.
89. Delord J, Thomas F, Benlyazid A, et al. Neo-adjuvant treatment with erlotinb in squamous cell carcinoma head and neck (SCCHN) patients before surgery provides an opportunity to find predictive factors of response. J Clin Oncol 2006; 24(18S): Abstract 5513.
90. Lee JW, Soung YH, Kim SY, et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11: 2879-82.
91. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 2006; 42: 109-11.
92. Mojica WD, Khoury T, Starostik P, Cheney RT. Frequency of gefitinib responder mutations in EGFR (+) squamous cell carcinoma of the head and neck. Proc Amer Assoc Cancer Res 2005; 46: Abstract 4204.
93. Na I, Kang H, Park Y, et al. EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. J Clin Oncol 2006; 24(18S): Abstract 10027.
94. Willmore-Payne C, Holden JA, Layfield LJ. Detection of EGFR-and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod Pathol 2006; 19: 634-40.
95. Murray S, Linardou H, Razis B, Pectasides D, Fountzilas G. Screening for EGFR mutations in patients with head and neck cancer treated with gefitinib on a compassionate-use program: A Hellenic Cooperative oncology group study. Ann Oncol 2006; 17: Abstract 578PD.
96. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006; 12: 5064-73.
97. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005; 97: 981-9.
98. Amado RM, Wolf M, Freeman D, et al. Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy. Eur J Cancer Suppl 2007; 5(6): Abstract 7LB.
99. Cappuzzo R, Finocchiaro G. Comprehensive assessment of molecular markers predicting response to cetuximab therapy in colorectal cancer. Eur J Cancer Suppl 2007; 5(4): Abstract 3002.
100. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-9.
101. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-7.
102. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007; 13: 2890-6.
103. Hoa M, Davis SL, Ames SJ, Spanjaard RA. Amplification of wildtype K-ras promotes growth of head and neck squamous cell carcinoma. Cancer Res 2002; 62: 7154-6.
104. Yarbrough WG, Shores C, Witsell DL, Weissler MC, Fidler ME, Gilmer TM. ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope 1994; 104: 1337-47.
105. Matsuda H, Konishi N, Hiasa Y, et al. Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions. J Oral Pathol Med 1996; 25: 232-8.
106. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology 2003; 17: 23-8.
107. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13: 3913-21.
108. Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6: 29-31.
109. Gotlib V, Khaled S, Lapko I, Mar N, Saif MW. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs 2006; 17: 1227-9.